Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pneumococcal Pneumonia Clear all
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

NCT00621504
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Not applicable Interventional

Pneumonia Vaccine Education Intervention Study

NCT06136832
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Vaccine
Interventions
Pneumococcal Vaccine Education
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 64 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

NCT05844423
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
32
States / cities
Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

NCT03803202
View directory record Official record
Conditions
Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
Interventions
ASP3772, PCV13, PPSV23
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
26
States / cities
Banning, California • San Diego, California • San Marcos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

NCT05420961
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, PCV15, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
717 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Glendale, Arizona • Tempe, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pneumonia Vaccine in Aging HIV Positive Individuals

NCT02558751
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
50 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

NCT04168190
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, Pneumovax™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
20
States / cities
Birmingham, Alabama • Mesa, Arizona • Coral Gables, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

NCT05526716
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, QIV, Matching Placebo for V116
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
56
States / cities
Phoenix, Arizona • Canoga Park, California • La Mesa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 21, 2026, 4:52 PM EDT
Recruiting No phase listed Observational

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941
View directory record Official record
Conditions
Pneumonia
Interventions
Diagnostic test on urine samples
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
12,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
40
States / cities
El Centro, California • Fontana, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 21, 2026, 4:52 PM EDT
Not listed Phase 2 Interventional

Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department

NCT00380679
View directory record Official record
Conditions
High Risk for Serious Influenza, High Risk for Pneumonia
Interventions
Influenza vaccination, Pneumococcal polysaccharide vaccination
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2006 · Synced Jul 21, 2026, 4:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage

NCT01109108
View directory record Official record
Conditions
Nasopharyngeal Carriage of S. Pneumoniae
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
9,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 1Phase 2 Interventional

Pneumococcal Adult-dose Ranging Immunization Study

NCT00169234
View directory record Official record
Conditions
Pneumonia
Interventions
PCV7, Prevnar®, Pneumovax 23
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
70 Years to 79 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 4 Interventional

Humoral Determinants of Immunity to Pneumococcal Infection

NCT00304382
View directory record Official record
Conditions
Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae
Interventions
Prevnar, Pneumovax
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

NCT04887948
View directory record Official record
Conditions
Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
Interventions
20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
27
States / cities
Anaheim, California • Walnut Creek, California • Coral Gables, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jul 21, 2026, 4:52 PM EDT
Terminated Phase 4 Interventional

Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days

NCT00237445
View directory record Official record
Conditions
Pneumonia
Interventions
telithromycin, azithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines

NCT03104075
View directory record Official record
Conditions
Pneumonia, Aging
Interventions
Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein, Pneumococcal Vaccine Polyvalent
Biological
Lead sponsor
The Jackson Laboratory
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

NCT00323557
View directory record Official record
Conditions
Leukemia
Interventions
Sargramostim (GM-CSF), Pneumococcal Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Jul 21, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

NCT03950856
View directory record Official record
Conditions
Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
V114, Prevnar 13™
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
2,340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
30
States / cities
Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 21, 2026, 4:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

NCT02294487
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Jul 21, 2026, 4:52 PM EDT